Weight Loss Drugs Race to Transform India’s Health Future

India has become a critical front in the global race for weight loss drugs, as Eli Lilly and Novo Nordisk battle for leadership in the country’s rapidly expanding obesity treatment market. Analysts warn that India could have the world’s second-largest overweight population by 2050, making it a pivotal arena for GLP-1 drugs such as Mounjaro, Wegovy, and Ozempic.  

Key Highlights

• Market Expansion: India’s obesity drug market has grown fivefold since 2021, reaching ₹6.28 billion, with projections to cross $1 billion within two years.  
• Competitive Strategies: Lilly gained early advantage with Mounjaro, while Novo Nordisk is countering through price reductions and accelerated launches.  
• Outreach Efforts: Both companies are investing heavily in doctor education, clinic partnerships, and advertising campaigns. Lilly has also engaged Bollywood celebrities to raise awareness.  
• Generics Challenge: Patent expiry on semaglutide in 2026 will allow over 20 Indian drugmakers, including Cipla, Sun Pharma, and Dr. Reddy’s, to launch cheaper versions at up to 60 percent lower cost.  
• Global Implications: Success in India could influence worldwide adoption of weight-loss drugs, given the country’s scale and sensitivity to pricing.  

Sources: Medical Dialogues, Business Standard, EconoTimes, Economic Times, South China Morning Post